Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss - Seite 3
Dr. William J. Evans
William J. Evans, PhD is an Adjunct Professor of Medicine in the Division of Geriatrics at the Duke University Medical Center and Human Nutrition in the Department of Nutritional Sciences at the
University of California, Berkeley. He previously was Vice President and head of the Muscle Metabolism Discovery Unit at GSK. He has served as laboratory director at the Reynolds Institute on Aging
at the University of Arkansas for Medical Sciences, the Noll Physiological Research Center at Penn State and as the Chief of the Human Physiology Laboratory at the Human Nutrition Research Center
on Aging at Tufts University. With an H-index of 124 and more than 78,000 citations he is the author or co-author of more than 350 publications in scientific journals and was the first to describe
sarcopenia. He is the co-inventor of the D3Creatine dilution method, a non-invasive and accurate measurement of muscle mass which is strongly related to health outcomes in older people. His work
has been featured in the PBS series, NOVA, Good Morning America, 20/20, CBS evening news, CNN, and the New York Times. Dr. Evans has been invited to testify before the US Senate Select Committee on
Aging on strategies to save Medicare. He is a founding member of the Society for Sarcopenia, Cachexia, and Wasting Disorders and recently received the Lifetime Achievement Award from the
International Conference on Frailty and Sarcopenia Research.
Lesen Sie auch
About Sarcopenic Obesity
According to the CDC, 41.5% of older adults have obesity in the United States and could benefit from a weight loss medication. Up to 34.4% of these obese patients over the age of 60 have sarcopenic
obesity. This large subpopulation of sarcopenic obese patients is especially at risk for taking GLP-1 drugs for weight loss as they already have critically low amount of muscle due to age-related
muscle loss. Further loss of muscle mass when taking a GLP-1 RA medication may lead to muscle weakness leading to poor balance, decreased gait speed, mobility disability, loss of independence,
falls, bone fractures and increased mortality which is a condition like age-related frailty. Because of the magnitude and speed of muscle loss while on GLP-1 RA therapy for weight loss, GLP-1 RA
drugs may accelerate frailty in older obese or overweight elderly patients.